Glaxo urges dissolvable tobacco removal
This article was originally published in The Tan Sheet
Executive Summary
The maker of nicotine replacement therapies including Nicorette gum and NicoDerm CQ patches urges FDA to order dissolvable tobacco products from the market until manufacturers prove they benefit public health. In a Sept. 17 comment on FDA's request for information on smokeless tobacco, Caroline Tillett, GlaxoSmithKline's head of smoking control research and development, notes the products are "marketed not as substitutes but to be used in addition to cigarettes." The letter says the American Heart Association rejects smokeless tobacco as a smoking-cessation treatment (1"The Tan Sheet" Sept. 20, 2010, In Brief). Strips and lozenges of smokeless tobacco are spitless, unlike earlier formulations, which manufacturers promote as an advantage. GSK says the products could attract consumers to begin tobacco use or promote smokers' use of both products. Although switching from cigarettes to smokeless tobacco may pose a health benefit, "there are not sufficient data to warrant recommending switching to a smokeless tobacco product as a means of reducing the risks associated with" smoking, the firm says. An FDA workshop Oct. 26-27 will study changing NRT labeling beyond the current 12-week indication, which GSK previously asked FDA to consider (2"The Tan Sheet" Sept. 6, 2010)
You may also be interested in...
FDA Will Mull OTC Smoking Cessation Long-Term Use As Support Builds
Participants at an FDA workshop will consider issues that could influence whether the agency extends the use of nicotine-replacement therapies beyond the current 12-week indication
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.